The development of a flow route to synthesize 3- benzyl-6-bromo-2-methoxyquinoline, an intermediate of an anti-TB drug, bedaquilin [PDF]
, 2022 SA has a high number of reported cases of multidrug-resistant tuberculosis (MDR-TB). Bedaquiline is a newly approved active ingredient of an anti-tuberculosis drug with high potency against MDR-TB.
Mpalala, Anele
core +1 more source
Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence
Journal of Experimental Pharmacology, 2020 Juilia Sellarès-Nadal, Joaquin Burgos, Vicenç Falcó, Benito Almirante Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Autonomous University of Barcelona, Barcelona, SpainCorrespondence: Benito ...
Sellarès-Nadal J +3 more
doaj
Oxazolidinones as versatile scaffolds in medicinal chemistry [PDF]
, 2023 Oxazolidinone is a five-member heterocyclic ring with several biological applications in medicinal chemistry. Among the three possible isomers, 2-oxazolidinone is the most investigated in drug discovery. Linezolid was pioneered as the first approved drug
Castagnolo, Daniele +4 more
core
Challenges and Advances in Tuberculosis and Mycobacterial Lung Diseases [PDF]
, 2022 The Special Issue of the journal Diagnostics entitled “Challenges and Advances in Tuberculosis and Mycobacterial Lung Diseases” encompasses research articles, case presentations, and literature reviews concerning the epidemiology, medical surveillance ...
core +1 more source
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. [PDF]
TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL).
Bigelow, Kristina +17 more
core +1 more source
Role for Linezolid in drug sensitive tuberculosis [PDF]
Tuberculosis (TB) continues to be a global challenge. Reducing the duration of TB treatment for drugsensitive TB (DSTB) has direct and distinct advantages.
Narendran, G +2 more
core +1 more source
Evolución clínico - epidemiológica de la tuberculosis en pacientes del centro de salud San Luis, Lima 2018-2022 [PDF]
, 2022 Objetivo: Detallar la evolución de la Tuberculosis (TB) en pacientes de Centro de Salud San Luis y sus características clínico-epidemiológicas. Material y Métodos: Fue un estudio de tipo observacional, descriptivo, transversal, retrospectivo. Se evaluó
Moreno Ayala, Morelia Ivett
core
Design, synthesis and anti-TB evaluation of 6 dialkylaminopyrimidine carboxamides [PDF]
, 2021 : Tuberculosis (TB) is an infectious airborne disease that is caused by Mycobacterium tuberculosis (Mtb). The World Health Organization (WHO) reported that TB was responsible for 1.4 million deaths worldwide in 2019. Most of these deaths occurred in poor
Tshinavhe, Ronewa
core +1 more source
Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo [PDF]
The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance.
Bahizire, E +14 more
core +1 more source
Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends [PDF]
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (M.tb) complex (MTBC), which includes M.tb as one of the causative bacteria. In contrast, non-tuberculous mycobacteria (NTM) refers to Mycobacterium spp. that do not cause TB or leprosy (MTBC spp.,
Amit Kadam +6 more
core +1 more source